The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.
With the aid of a cane, Dr. Lucius Sinks moved briskly through the dining room at the Boar’s Head Inn in Charlottesville, VA. At the time, he was well into his ’80s. But he remained a formidable presence, with thick white hair, dark eyes, and a wry smile.
Last week pediatric oncology lost another pioneer in the field, Lucius Sinks. He was 91.
The World Health Organization and St. Jude Children’s Research Hospital Dec. 13 announced plans to establish the Global Platform for Access to Childhood Cancer Medicines to provide an uninterrupted supply of quality-assured childhood cancer medicines to low- and middle-income countries.
FDA has approved Rituxan (rituximab) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).
Tara O. Henderson was named the service line chief of pediatric cancer and blood diseases at the Chicagoland Children’s Health Alliance, a collaboration between University of Chicago Medicine Comer Children’s Hospital, Advocate Children’s Hospital, and Pediatrics at NorthShore University HealthSystem.
